Literature DB >> 28741195

Comparison of Prognostic Abilities Among Preoperative Laboratory Data Indices in Patients with Resectable Gastric and Esophagogastric Junction Adenocarcinoma.

Masayuki Urabe1, Hiroharu Yamashita2, Toshiaki Watanabe3, Yasuyuki Seto2.   

Abstract

BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), modified Glasgow prognostic score (mGPS) and prognostic nutritional index (PNI) are simple indices determined employing laboratory data alone and have been used to predict the clinical outcomes of patients with esophagogastric tumors. However, prior results were generally based on analyzing dichotomous data with arbitrary cutoff values. This retrospective study aims to assess prognostic utilities of preoperative NLR, PLR, LMR, mGPS and PNI, as continuous variables, in gastric cancer (GC) and adenocarcinoma of esophagogastric junction (AEG).
METHODS: Preoperative data from 1363 patients who underwent surgery for GC/AEG were retrospectively examined. Survival time was evaluated applying the Cox proportional hazard model to both univariate and multivariate estimates of clinicopathological factors and the aforementioned indices as continuous variables.
RESULTS: Preoperatively, each index value was significantly associated with T and N stages, as well as lymphatic involvement and venous involvement. On univariate Cox regression analysis, preoperative NLR, PLR, LMR and PNI were significantly associated with overall survival (OS) and relapse-free survival (RFS). Preoperative mGPS was associated only with RFS. On multivariate Cox regression analysis, preoperative PNI was independently associated with OS and RFS (hazard ratio [HR] 0.62 per 10-unit increase, 95% CI 0.47-0.82, p < 0.001; HR 0.60, 95% CI 0.46-0.78, p < 0.001, respectively), as age, gender, tumor location, T and N stages and venous involvement, while other indices lost independence on multivariate analysis.
CONCLUSIONS: Preoperative PNI, a score related to nutritional status, is of importance for predicting long-term outcomes in patients with GC and AEG.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28741195     DOI: 10.1007/s00268-017-4146-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  36 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer.

Authors:  Kotaro Hirashima; Masayuki Watanabe; Hironobu Shigaki; Yu Imamura; Satoshi Ida; Masaaki Iwatsuki; Takatsugu Ishimoto; Shiro Iwagami; Yoshifumi Baba; Hideo Baba
Journal:  J Gastroenterol       Date:  2013-07-03       Impact factor: 7.527

3.  The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer?

Authors:  Eun Young Kim; Jin Won Lee; Han Mo Yoo; Cho Hyun Park; Kyo Young Song
Journal:  Ann Surg Oncol       Date:  2015-03-25       Impact factor: 5.344

4.  [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients].

Authors:  T Onodera; N Goseki; G Kosaki
Journal:  Nihon Geka Gakkai Zasshi       Date:  1984-09

5.  Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan.

Authors:  Chika Kusano; Takuji Gotoda; Christopher J Khor; Hitoshi Katai; Hoichi Kato; Hirokazu Taniguchi; Tadakazu Shimoda
Journal:  J Gastroenterol Hepatol       Date:  2008-11       Impact factor: 4.029

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.

Authors:  A Tsuburaya; J Mizusawa; Y Tanaka; N Fukushima; A Nashimoto; M Sasako
Journal:  Br J Surg       Date:  2014-03-25       Impact factor: 6.939

8.  Serum albumin and muscle measures in a cohort of healthy young and old participants.

Authors:  E M Reijnierse; M C Trappenburg; M J Leter; S Sipilä; L Stenroth; M V Narici; J Y Hogrel; G Butler-Browne; J S McPhee; M Pääsuke; H Gapeyeva; C G M Meskers; A B Maier
Journal:  Age (Dordr)       Date:  2015-08-27

9.  Sarcopenia is an Independent Predictor of Severe Postoperative Complications and Long-Term Survival After Radical Gastrectomy for Gastric Cancer: Analysis from a Large-Scale Cohort.

Authors:  Cheng-Le Zhuang; Dong-Dong Huang; Wen-Yang Pang; Chong-Jun Zhou; Su-Lin Wang; Neng Lou; Liang-Liang Ma; Zhen Yu; Xian Shen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

10.  The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer.

Authors:  Joseph C Y Chan; David L Chan; Connie I Diakos; Alexander Engel; Nick Pavlakis; Anthony Gill; Stephen J Clarke
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

View more
  8 in total

1.  Total iron-binding capacity is a novel prognostic marker after curative gastrectomy for gastric cancer.

Authors:  Hiroshi Sawayama; Masaaki Iwatsuki; Daisuke Kuroda; Tasuku Toihata; Tomoyuki Uchihara; Yuki Koga; Taisuke Yagi; Yuki Kiyozumi; Tsugio Eto; Yukiharu Hiyoshi; Takatsugu Ishimoto; Yoshifumi Baba; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2018-04-09       Impact factor: 3.402

2.  Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis.

Authors:  Yanhong Li; Mei Wang; Xueping Zhu; Xu Cao; Yi Wu; Fang Fang
Journal:  Dis Markers       Date:  2019-08-22       Impact factor: 3.434

3.  Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer.

Authors:  Hiroyuki Inoue; Toshiyuki Kosuga; Takeshi Kubota; Hirotaka Konishi; Atsushi Shiozaki; Kazuma Okamoto; Hitoshi Fujiwara; Eigo Otsuji
Journal:  World J Surg Oncol       Date:  2021-06-12       Impact factor: 2.754

Review 4.  Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer.

Authors:  Can-Tong Liu; Chao-Qun Hong; Xu-Chun Huang; En-Min Li; Yi-Wei Xu; Yu-Hui Peng
Journal:  J Cancer       Date:  2020-04-27       Impact factor: 4.207

5.  Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis.

Authors:  Xunlei Zhang; Wenjing Zhao; Yang Yu; Xue Qi; Li Song; Chenfei Zhang; Guoxing Li; Lei Yang
Journal:  World J Surg Oncol       Date:  2020-07-30       Impact factor: 2.754

6.  Preoperative Neutrophil Lymphocyte Ratio Can Be Used as a Predictor of Prognosis in Patients With Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta Analysis.

Authors:  Xiao-Bo Liu; Zi-Ye Gao; Qing-Hui Zhang; Sandeep Pandey; Bo Gao; Fan Yang; Qiang Tong; Sheng-Bao Li
Journal:  Front Oncol       Date:  2020-02-21       Impact factor: 6.244

7.  Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis.

Authors:  Yuan Chen; Ming Jin; Yingjie Shao; Guoping Xu
Journal:  Dis Markers       Date:  2019-11-04       Impact factor: 3.434

Review 8.  Systematic Review of Prognostic Role of Blood Cell Ratios in Patients with Gastric Cancer Undergoing Surgery.

Authors:  Sabine Schiefer; Naita Maren Wirsik; Eva Kalkum; Svenja Elisabeth Seide; Henrik Nienhüser; Beat Müller; Adrian Billeter; Markus W Büchler; Thomas Schmidt; Pascal Probst
Journal:  Diagnostics (Basel)       Date:  2022-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.